Clinical Scorecard: Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution
At a Glance
Category
Detail
Condition
Key Mechanisms
Immunoembolization (IE) combines ischemic tumor control with localized immune stimulation, primarily using GM-CSF and IL-2, delivered via transarterial routes.
Target Population
Care Setting
Key Highlights
highlight_4
Guideline-Based Recommendations
Diagnosis
Management
Immunoembolization is a viable option for liver-directed therapy in mUM.
Consider follow-up imaging and clinical assessments at regular intervals post-IE.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with liver-dominant mUM, median age 62 years, including diverse ethnic backgrounds.
Clinical Best Practices
Consider patient history of systemic therapy when planning treatment.
Utilize IE as part of a comprehensive treatment strategy for liver-dominant mUM, including systemic therapies as needed.
Encourage participation in prospective trials to enhance treatment outcomes.
